Foghorn Therapeutics
FHTX
47 hedge funds and large institutions have $470M invested in Foghorn Therapeutics in 2020 Q4 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
65.03% more ownership
Funds ownership: 0% → 65.03% (+65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$243M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.4M |
| 3 |
AG
Artal Group
Luxembourg
|
+$33M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$19.2M |
| 5 |
BlackRock
New York
|
+$12.9M |
Top Sellers
FHTX Hedge Fund Activity: Q4 2020 in Review
47 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q4 2020, worth a combined $470M.
Buyers outnumbered sellers: 47 funds opened new FHTX positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Flagship Pioneering, opening a new position worth an estimated $243M.
- 47 institutional investors held Foghorn Therapeutics (FHTX) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $470M of Foghorn Therapeutics stock for Q4 2020.
- 47 funds opened new Foghorn Therapeutics positions in Q4 2020 and 0 closed out, a net change of +47 holders.
- The largest Foghorn Therapeutics buyer in Q4 2020 was Flagship Pioneering, an estimated $243M added.
Based on aggregated 13F filings for Q4 2020.